Company intelligence / Profile preview
Shanghai Jingshan Biotechnology
Shanghai, Shanghai, Chinajingshanbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Jingshan Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on developing innovative antibody-based therapies for cancer and autoimmune disorders. The company utilizes its proprietary J-Body platform to engineer bispecific and multi-specific antibodies with optimized drug-like properties and enhanced therapeutic windows. Its lead program, JS001, is a bispecific antibody targeting both PD-L1 and CD47, currently undergoing clinical evaluation for advanced malignancies. Jingshan Bio aims to address unmet medical needs through its deep expertise in protein engineering and immunology.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shanghai Jingshan Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Jingshan Biotechnology.